X4 Pharmaceuticals (XFOR) Consolidated Net Income (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Consolidated Net Income for 10 consecutive years, with -$16.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Consolidated Net Income rose 37.23% year-over-year to -$16.2 million; the trailing twelve-month figure through Jun 2026 stood at -$90.1 million (up 11.61% YoY), and the FY2025 full-year result was -$79.2 million, down 111.48% from the prior year.
• Consolidated Net Income advanced to -$16.2 million in Q2 2026 per XFOR's latest filing, from -$20.2 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $90.8 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
• Historically, Consolidated Net Income has averaged -$19.3 million across 5 years, with a median of -$22.9 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Consolidated Net Income jumped 263.04% in 2024, then slumped 7277.66% in 2026.
• Over 5 years, Consolidated Net Income stood at -$29.1 million in 2022, then jumped by 34.27% to -$19.1 million in 2023, then tumbled by 108.16% to -$39.8 million in 2024, then jumped by 39.92% to -$23.9 million in 2025, then jumped by 32.47% to -$16.2 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$16.2 million, -$20.2 million, and -$23.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.